AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19026497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear factor analysis
Number of subjects: 6259
Study 19026497 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption items, age, and gender as predictors
Number of subjects: 6259
Study 19026497 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class factor analysis
Number of subjects: 6259
Study 19026497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for consumption, age, and gender
Number of subjects: 6259
Study 17250746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 l/min oxygen in air (50% oxygen)
Number of subjects: 32
Study 17250746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l/min oxygen in air (50% oxygen)
Number of subjects: 32
Study 17250746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 l/min (33% oxygen)
Number of subjects: 32
Study 17250746 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 l/min oxygen in nitrous oxide (33% oxygen)
Number of subjects: 32
Study 17250746 — intervention group
Group type: COMPARATOR
Intervention: Lowest oxygen in air group (1 l/min)
Number of subjects: 32
Study 15839740 — intervention group
Group type: EXPERIMENTAL
Intervention: co-artemether (six doses)
Number of subjects: 497
Study 15839740 — intervention group
Group type: COMPARATOR
Intervention: CQ/SP (three doses of CQ and one dose of SP)
Number of subjects: 497
Study 12020485 — intervention group
Group type: COMPARATOR
Intervention: Group A (2-3 leads with ST-segment elevation)
Number of subjects: 8731
Study 12020485 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (4-5 leads with ST-segment elevation)
Number of subjects: 8731
Study 12020485 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (6-7 leads with ST-segment elevation)
Number of subjects: 8731
Study 12020485 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (more than 8 leads with ST-segment elevation)
Number of subjects: 8731
Study 10453586 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture and routine treatments (group 1, n = 31)
Number of subjects: 64
Study 10453586 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (group 2, n = 33)
Number of subjects: 64
Study 7530054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas antigen expression in acute myelogenous leukemia (AML)
Number of subjects: 95
Study 7530054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas antigen expression in acute lymphoblastic leukemia (ALL)
Number of subjects: 95
Study 7530054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas antigen expression in leukemic lymphoma
Number of subjects: 95
Study 7530054 — intervention group
Group type: COMPARATOR
Intervention: Fas antigen expression in normal controls
Number of subjects: 95
Study 7530054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fas antigen expression in plasma cell leukemia
Number of subjects: 95
Study 7530054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical relevance of Fas positivity in AML
Number of subjects: 95
Study 1882025 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress/type A behavior reduction program
Number of subjects: 20
Study 1882025 — intervention group
Group type: COMPARATOR
Intervention: Control group (officer nonparticipants)
Number of subjects: 20
Study 6808548 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-min frequency counts collected over a period of 11 weeks
Number of subjects: 6
Study 6808548 — intervention group
Group type: EXPERIMENTAL
Intervention: Independently obtained rating scale scores
Number of subjects: 6
Study 30919411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular screening examination using low-dose non-contrast CT, ankle and brachial BP measurements, and blood tests
Number of subjects: 16768
Study 30919411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular screening examination
Number of subjects: 16768
Study 30919411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular screening
Number of subjects: 16768
Study 30376859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 60
Study 30376859 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 60
Study 27170351 — intervention group
Group type: EXPERIMENTAL
Intervention: Qiaoshao Formula (QSF)
Number of subjects: 60
Study 27170351 — intervention group
Group type: COMPARATOR
Intervention: Dapoxetine
Number of subjects: 60
Study 25154849 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous paravertebral nerve block (PVB) with 0.2% ropivacaine 250 ml in continuous infusion, assisted with intravenous morphine patient‐controlled analgesia.
Number of subjects: 60
Study 25154849 — intervention group
Group type: COMPARATOR
Intervention: Control group (CEA) with 0.2% ropivacaine 250 ml in continuous infusion, assisted with intravenous morphine patient‐controlled analgesia.
Number of subjects: 60
Study 22134467 — intervention group
Group type: EXPERIMENTAL
Intervention: Moveable platform training
Number of subjects: 24
Study 22134467 — intervention group
Group type: COMPARATOR
Intervention: Normal walking trials (Control)
Number of subjects: 24
Study 20662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiki
Number of subjects: 0
Study 20662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat
Number of subjects: 0
Study 20662568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Diagnostic Context
Number of subjects: 0
Study 17215846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored regimen based on CYP2C19 status and bacterial susceptibility to clarithromycin
Number of subjects: 300
Study 17215846 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (lansoprazole 30 mg b.i.d., clarithromycin 400 mg b.i.d., amoxicillin 750 mg b.i.d. for 1 week)
Number of subjects: 300
Study 17215846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored regimen
Number of subjects: 300
Study 17215846 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 300
Study 15130866 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hip responses in older children
Number of subjects: 41
Study 15130866 — intervention group
Group type: COMPARATOR
Intervention: Passive hip-dominant responses in least experienced walkers
Number of subjects: 41
Study 12387471 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal support group run weekly with a facilitator, starting two weeks postpartum.
Number of subjects: 1004
Study 12387471 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal support manual, posted two weeks postpartum.
Number of subjects: 1004
Study 12387471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1004
Study 9796225 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning tasks (computer software package, building a model car) over a one‐, three‐, or five‐trial period
Number of subjects: 0
Study 9796225 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of playing time for melodies of varying familiarity (recently learned, well learned, extremely well learned) by novice and experienced pianists
Number of subjects: 0
Study 7707448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mebendazole
Number of subjects: 2471
Study 7707448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2471
Study 2616586 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam (200 mg/24 h)
Number of subjects: 18
Study 2616586 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (150 mg/24 h)
Number of subjects: 18
Study 467194 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus (MDA) during general anesthesia
Number of subjects: 156
Study 467194 — intervention group
Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy (LSS) during local anesthesia
Number of subjects: 156
Study 467194 — intervention group
Group type: COMPARATOR
Intervention: Lateral subcutaneous sphincterotomy (LSS)
Number of subjects: 156
Study 467194 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus (MDA)
Number of subjects: 156
Study 467194 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual dilatation of the anus (MDA) and Lateral subcutaneous sphincterotomy (LSS)
Number of subjects: 156
Study 31213097 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost therapy
Number of subjects: 39
Study 31213097 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 39
Study 28560780 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural agents (propolis, aloe vera, calendula, chamomile)
Number of subjects: 107
Study 28560780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 25613308 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 3035
Study 25613308 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3035
Study 22835005 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nonsurgical periodontal therapy before 24 gestational weeks (n = 30)
Number of subjects: 60
Study 22835005 — intervention group
Group type: COMPARATOR
Intervention: Supragingival calculus removal (n = 30, control group)
Number of subjects: 60
Study 22754923 — intervention group
Group type: EXPERIMENTAL
Intervention: O2 administered via nasal cannula for the first 10 minutes, followed by 10 minutes with O2 bar on without O2.
Number of subjects: 30
Study 22754923 — intervention group
Group type: COMPARATOR
Intervention: O2 bar remained on without O2 being administered for the first 10 minutes, followed by 10 minutes of O2 via nasal cannula.
Number of subjects: 30
Study 19309389 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up therapy (n = 293)
Number of subjects: 519
Study 19309389 — intervention group
Group type: COMPARATOR
Intervention: Step-down therapy (n = 226)
Number of subjects: 519
Study 17365932 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + Losartan 50 mg
Number of subjects: 21
Study 17365932 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + Ramipril 5 mg
Number of subjects: 21
Study 17365932 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily + Carvedilol 25 mg
Number of subjects: 21
Study 15096406 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline, 2 mg/d for 1 year
Number of subjects: 404
Study 15096406 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline, 1 mg/d for 1 year
Number of subjects: 404
Study 15096406 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months followed by rasagiline, 2 mg/d for 6 months
Number of subjects: 404
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Nilvadipine
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Hydrochlorothiazide
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Bisoprolol
Number of subjects: 16
Study 11549204 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril 10 mg combined with Hydrochlorothiazide, Bisoprolol, or Nilvadipine
Number of subjects: 16
Study 9041068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (R)
Number of subjects: 228
Study 9041068 — intervention group
Group type: COMPARATOR
Intervention: Hospital-treatment group (H)
Number of subjects: 228
Study 8177681 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture
Number of subjects: 289
Study 8177681 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed Word, Picture + Spoken Word
Number of subjects: 289
Study 8177681 — intervention group
Group type: COMPARATOR
Intervention: Spoken Word, Printed Word
Number of subjects: 289
Study 8177681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster index score
Number of subjects: 289
Study 3123115 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 49
Study 3123115 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 49
Study 29987375 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy (ETV)
Number of subjects: 158
Study 29987375 — intervention group
Group type: COMPARATOR
Intervention: Shunt
Number of subjects: 158
Study 25917562 — intervention group
Group type: EXPERIMENTAL
Intervention: High satisfaction with neighborhood
Number of subjects: 409
Study 25917562 — intervention group
Group type: EXPERIMENTAL
Intervention: Low satisfaction with neighborhood
Number of subjects: 409
Study 25917562 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood poverty
Number of subjects: 409
Study 25675063 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 5 mL (Group A)
Number of subjects: 32
Study 25675063 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4.5 mL + 20 mg of triamcinolone 0.5 mL (Group B)
Number of subjects: 32
Study 25675063 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 mL + 40 mg of triamcinolone 1 mL (Group C)
Number of subjects: 32
Study 25675063 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 32
Study 22961576 — intervention group
Group type: EXPERIMENTAL
Intervention: LOGIC-Insulin algorithm-guided glycemic control (LOGIC-C)
Number of subjects: 300
Study 22961576 — intervention group
Group type: COMPARATOR
Intervention: Nurse-directed glycemic control (Nurse-C)
Number of subjects: 300
Study 20491750 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g/day for 5 days
Number of subjects: 142
Study 20491750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 18440447 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 1mg
Number of subjects: 33
Study 18440447 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone >or=5mg
Number of subjects: 33
Study 18440447 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (all doses)
Number of subjects: 33
Study 16554517 — intervention group
Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 32
Study 16554517 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 32
Study 12618276 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg per day)
Number of subjects: 50
Study 12618276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10887384 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cigarette smokers (S)
Number of subjects: 22
Study 10887384 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (NS)
Number of subjects: 22
Study 8756362 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose preoperative radiation ( > or = 45 Gray [Gy]) followed by surgical resection (Group A)
Number of subjects: 297
Study 8756362 — intervention group
Group type: COMPARATOR
Intervention: Selective postoperative radiation (45‐50 Gy) after initial curative surgery (Group B)
Number of subjects: 297
Study 8756362 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (Group A)
Number of subjects: 297
Study 8756362 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiation (Group B)
Number of subjects: 297
Study 1574364 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced to drink according to the hospital's nursing care plan
Number of subjects: 74
Study 1574364 — intervention group
Group type: COMPARATOR
Intervention: Control over fluid intake
Number of subjects: 74
Study 3886564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam 1 g b.i.d. for 7 to 14 days
Number of subjects: 82
Study 3886564 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole 1 g t.i.d. for 7 to 14 days
Number of subjects: 82
Study 30569763 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐11101 (biosimilar darbepoetin‐alfa)
Number of subjects: 0
Study 30569763 — intervention group
Group type: COMPARATOR
Intervention: NESP
Number of subjects: 0
Study 30569763 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD‐11101
Number of subjects: 0
Study 30376084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV) administered during national health week (NHW) to 1 child under 5 in vaccinated households.
Number of subjects: 466
Study 30376084 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated households).
Number of subjects: 466
Study 27323337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (R) at a dose of 500 mg/bid
Number of subjects: 40
Study 27323337 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers or calcium-channel blockers (control)
Number of subjects: 40
Study 27323337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (R)
Number of subjects: 40
Study 24558028 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex lymphedema therapy (CLT)
Number of subjects: 31
Study 24558028 — intervention group
Group type: COMPARATOR
Intervention: Graduated compression stockings (30-40 mmHg)
Number of subjects: 31
Study 24558028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 31
Study 22154315 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in patients <75 years old
Number of subjects: 936
Study 22154315 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in patients ≥75 years old
Number of subjects: 936
Study 20851872 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-to-moderate CKD
Number of subjects: 435
Study 17594783 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa therapy in patients with PD
Number of subjects: 0
Study 17594783 — intervention group
Group type: COMPARATOR
Intervention: Patients with PD not receiving L-dopa
Number of subjects: 0
Study 17594783 — intervention group
Group type: COMPARATOR
Intervention: Patients without PD (control group)
Number of subjects: 0
Study 16253062 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy using the Ligasure system
Number of subjects: 30
Study 16253062 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic radical nephrectomy
Number of subjects: 30
Study 12153376 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 146
Study 12153376 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1.5 mg/kg once a day)
Number of subjects: 146
Study 12153376 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 146
Study 10076482 — intervention group
Group type: COMPARATOR
Intervention: Community-level intervention promoting consistent condom use and bleach use, involving role-model stories, distribution of condoms and bleach, and encouragement from community members.
Number of subjects: 15205
Study 10076482 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to the intervention (role-model stories, condoms, bleach).
Number of subjects: 15205
Study 7671981 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic occlusion
Number of subjects: 61
Study 7671981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild stroke
Number of subjects: 61
Study 7671981 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate stroke
Number of subjects: 61
Study 7671981 — intervention group
Group type: EXPERIMENTAL
Intervention: Watershed ischemia
Number of subjects: 61
Study 2137345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 0
Study 2137345 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 0
Study 7033157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 1 gm IM every 6 hrs for 8 doses and Tobramycin 1 mg/kg IM for 1 dose, starting 2 hrs prior to surgery
Number of subjects: 37
Study 7033157 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 37
Study 7033157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole and Tobramycin
Number of subjects: 37
Study 31551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 112
Study 31551147 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 112
Study 26615912 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction and weight-reduction program with nutritional education every 2 weeks for 2 months
Number of subjects: 82
Study 26615912 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 25-hydroxy vitamin D concentration <10 ng/ml
Number of subjects: 82
Study 26117157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 120mg/d
Number of subjects: 231
Study 26117157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 160mg/d
Number of subjects: 231
Study 26117157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40/80mg/d
Number of subjects: 231
Study 26117157 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine XR 200-800mg/d
Number of subjects: 231
Study 23183541 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated up-dosing regimen (0.1-0.3-0.5 ml in weekly intervals)
Number of subjects: 146
Study 23183541 — intervention group
Group type: COMPARATOR
Intervention: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 ml in weekly intervals)
Number of subjects: 146
Study 23183541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 146
Study 21711202 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Therapy program (YT)
Number of subjects: 18
Study 21711202 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (WL)
Number of subjects: 18
Study 19628124 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078
Study 19628124 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078
Study 16922792 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin-B-lipid-complex (ABLC) prophylaxis, 4 mg/kg, twice weekly starting on day +30 for patients on prednisone ≥30 mg/day.
Number of subjects: 100